Skip to search boxSkip to navigationSkip to main content

Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter

  • Catherine A. Vaughan
    ,
  • Isabella Pearsal
    ,
  • Shilpa Singh
    ,
  • Brad Windle
    ,
  • Swati P. Deb
    ,
  • Steven R. Grossman
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Human lung cancers harboring gain-of-function (GOF) p53 alleles express higher levels of the epidermal growth factor receptor (EGFR). We demonstrate that a number of GOF p53 alleles directly upregulate EGFR. Knock-down of p53 in lung cancer cells lowers EGFR expression and reduces tumorigenicity and other GOF p53 properties. However, addiction of lung cancer cells to GOF p53 can be compensated by overexpressing EGFR, suggesting that EGFR plays a critical role in addiction. Chromatin immunoprecipitation (ChIP) using lung cancer cells expressing GOF p53 alleles showed that GOF p53 localized to the EGFR promoter. The sequence where GOF p53 is found to interact by ChIP seq can act as a GOF p53 response element. The presence of GOF p53 on the EGFR promoter increased histone H3 acetylation, indicating a mechanism whereby GOF p53 enhances chromatin opening for improved access to transcription factors (TFs). ChIP and ChIP-re-ChIP with p53, Sp1 and CBP histone acetylase (HAT) antibodies revealed docking of GOF p53 on Sp1, leading to increased binding of Sp1 and CBP to the EGFR promoter. Up-regulation of EGFR can occur via GOF p53 contact at other novel sites in the EGFR promoter even when TAD-I is inactivated; these sites are used by both intact and TAD-I mutated GOF p53 and might reflect redundancy in GOF p53 mechanisms for EGFR transactivation. Thus, the oncogenic action of GOF p53 in lung cancer is highly dependent on transactivation of the EGFR promoter via a novel transcriptional mechanism involving coordinated interactions of TFs, HATs and GOF p53.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 12426-12446 (21 pages)

Journal (Volume, Issue Number)

Oncotarget (Volume 7, Issue 11)

Publication milestones

  • Published - 03/15/2016

Publication status

Published - 03/15/2016

ISSN

1949-2553

Publication IDs

  • Scopus: 84962783991
  • PubMed: 26820293

Publication metrics

Metrics

SciVal
FWCI
0.53
SciVal
Author count
8
SciVal
citations
12
SciVal
Paper percentile
76
Scopus
citations
Fractional count
1
Fractional count
0.13
Fractional count
7
Fractional count
0.88
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
27
Citation count
17

Funding Details

This work was supported by grants from NIH to Sumitra Deb (CA70712 and CA121144) and Swati Palit Deb (CA74172), Pilot Project Awards from the VCU Massey Cancer Center to Sumitra Deb, Steve R. Grossman, Swati Palit Deb, Andrew Yeudall and Brad Windle, a grant from the Jeffress Memorial Trust to Brad Windle and in part with funding from NIH-NCI P30CA016059 to VCU Massey Cancer Center.
FundersFunding numbers
NCI, NIH
P30CA016059
NIH
CA74172, CA70712
NCI
R01CA121144
Thomas F. and Kate Miller Jeffress Memorial Trust
-